Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.73 |
| ▸ | CA1 | P00915 | 15/20 | 0.73 |
| ▸ | CA9 | Q16790 | 12/20 | 0.73 |
| ▸ | CA12 | O43570 | 10/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.65 |
| ▸ | CA5A | P35218 | 3/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.65 |
| ▸ | CA7 | P43166 | 3/20 | 0.65 |
| ▸ | CA3 | P07451 | 2/20 | 0.65 |
| ▸ | CA6 | P23280 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | STS | P08842 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671469 | 0.86 | CA1 (1.00) | CA2CA1CA9CA12CA7 | |
| Benzenesulfonamide SCHEMBL28096249 | 0.85 | CA9 (0.64) | CA2CA1CA9CA12CA14 | |
| SCHEMBL18361578 | 0.84 | CA2 (0.69) | CA2CA1CA9CA12CA7 | |
| SCHEMBL12652094 | 0.82 | CA2 (0.67) | CA2CA1CA9CA12CA14 | |
| SCHEMBL4027167 | 0.81 | MAPT (0.61) | CA2CA1CA9CA12STS | |
| SCHEMBL18361714 | 0.80 | CA2 (0.53) | CA2CA1CA9CA12CA14 | |
| SCHEMBL396977 | 0.80 | CA2 (0.58) | CA2CA1CA9CA12CA14 | |
| SCHEMBL11839666 | 0.79 | CA2 (0.57) | CA2CA1CA9CA12CA14 | |
| SCHEMBL176891 | 0.79 | CA2 (1.00) | CA2CA1CA9CA12CA14 | |
| SCHEMBL7646230 | 0.79 | ALDH1A1 (0.58) | CA2CA1CA9CA12STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745119-A1 | ISOCYANATE COMPOSITION | Hanwha Solutions Corporation (KR) | 2026-05-20 | — | — | EP | claimed |
| CN-119528773-A | N-alkylation method of sulfonamide compound | 赣南医科大学 | 2025-02-28 | — | — | CN | claimed |
| WO-2025042219-A1 | ISOCYANATE COMPOSITION | 한화솔루션 주식회사 | 2025-02-27 | — | — | WO | claimed |
| JP-58105957-A | — | — | None | — | — | JP | disclosed |
| EP-4745119-A1 | ISOCYANATE COMPOSITION | Hanwha Solutions Corporation (KR) | 2026-05-20 | — | — | EP | disclosed |
| CN-119528773-A | N-alkylation method of sulfonamide compound | 赣南医科大学 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025042219-A1 | ISOCYANATE COMPOSITION | 한화솔루션 주식회사 | 2025-02-27 | — | — | WO | disclosed |
| WO-2025002289-A1 | PYRAZOLOHETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 湖南九典制药股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-119219638-A | Pyrazoloheteroaryl compound and preparation method and application thereof | 湖南九典制药股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-3615525-B1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5504215-A | Substituted pyrazolyl benzenesulfonamide compounds for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1996-04-02 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
| EP-0143627-A1 | An improved process for preparing sulfonamides | ELI LILLY AND COMPANY (US) | 1985-06-05 | — | — | EP | disclosed |
| JP-S58105957-A | PREPARATION OF P-ACETYLBENZENSULFONAMIDE | NIPPON KAYAKU CO LTD | 1983-06-24 | — | — | JP | disclosed |
| US-4312990-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-26 | — | — | US | disclosed |
| US-4137408-A | BACTERICIDES, ANTIBIOTICS | WARNER-LAMBERT (US) | 1979-01-30 | — | — | US | disclosed |
| US-4101661-A | PENICILLINS, CEPHALOSPORINS | WARNER-LAMBERT (US) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA2 2434/4885CA1 4141/4885CA9 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.